PE20091186A1 - DERIVADO DE y-LACTONA DE ESTEROIDE DE ACIDO 15,16-METILEN-17-HIDROXI-19-NOR-21-CARBOXILICO, SU USO Y MEDICAMENTO QUE LO CONTIENE - Google Patents

DERIVADO DE y-LACTONA DE ESTEROIDE DE ACIDO 15,16-METILEN-17-HIDROXI-19-NOR-21-CARBOXILICO, SU USO Y MEDICAMENTO QUE LO CONTIENE

Info

Publication number
PE20091186A1
PE20091186A1 PE2008002192A PE2008002192A PE20091186A1 PE 20091186 A1 PE20091186 A1 PE 20091186A1 PE 2008002192 A PE2008002192 A PE 2008002192A PE 2008002192 A PE2008002192 A PE 2008002192A PE 20091186 A1 PE20091186 A1 PE 20091186A1
Authority
PE
Peru
Prior art keywords
methylen
lactone
acid
alkyl
gamma
Prior art date
Application number
PE2008002192A
Other languages
English (en)
Inventor
Klar Ulrich
Joachim Kuhnke
Rolf Bohlmann
Jan Huebner
Sven Ring
Thomas Frenzel
Frederik Menges
Steffen Borden
Peter Muhn
Katja Prelle
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40627627&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091186(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20091186A1 publication Critical patent/PE20091186A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE GAMMA-LACTONA DE ESTEROIDE DE ACIDO 15,16-METILEN-ACIDO 17-HIDROXI-19-NOR-21-CARBOXILICO DONDE Z ES O, DOS H, NOR', ENTRE OTROS, DONDE R' ES H, ALQUILO(C1-C10), ARILO, ENTRE OTROS; R4 ES H O HALOGENO; R6a Y R6b SON CADA UNO H, ALQUILO(C1-C10), ALQUENILO(C2-C10), ENTRE OTROS; R7 ES H, ALQUILO(C1-C10), CICLOALQUILO(C3-C6), ENTRE OTROS; R18 ES H O ALQUILO(C1-C3). SON COMPUESTOS PREFERIDOS: GAMMA-LACTONA DE ACIDO 17BETA-HIDROXI-15BETA,16BETA-METILEN-19-NOR-17ALFA-PREGNA-4,20(Z)-DIEN-3-ONA-21-CARBOXILIXO, GAMMA-LACTONA DE ACIDO 17BETA-HIDROXI-7BETA-METIL-15ALFA,16ALFA-METILEN-19-NOR-17ALFA-PREGNA-4,20(Z)-DIEN-3-ONA-21-CARBOXILICO, GAMMA-LACTONA DE ACIDO 17BETA-HIDROXI-7ALFA-METIL-15BETA,16BETA-METILEN-19-NOR-17ALFA-PREGNA-4,20(Z)-DIEN-3-ONA-21-CARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN EFECTO GESTAGENICO SIENDO UTILES EN LA CONTRACEPCION Y EL TRATAMIENTO DE TRASTORNOS PRE Y POSMENOPAUSICOS
PE2008002192A 2007-12-29 2008-12-29 DERIVADO DE y-LACTONA DE ESTEROIDE DE ACIDO 15,16-METILEN-17-HIDROXI-19-NOR-21-CARBOXILICO, SU USO Y MEDICAMENTO QUE LO CONTIENE PE20091186A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007063501A DE102007063501A1 (de) 2007-12-29 2007-12-29 15, 16-Methylen-17-hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
PE20091186A1 true PE20091186A1 (es) 2009-09-06

Family

ID=40627627

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002192A PE20091186A1 (es) 2007-12-29 2008-12-29 DERIVADO DE y-LACTONA DE ESTEROIDE DE ACIDO 15,16-METILEN-17-HIDROXI-19-NOR-21-CARBOXILICO, SU USO Y MEDICAMENTO QUE LO CONTIENE

Country Status (25)

Country Link
US (1) US20110015162A1 (es)
EP (1) EP2238150B1 (es)
JP (1) JP5643107B2 (es)
KR (1) KR20100094999A (es)
CN (1) CN101910191B (es)
AR (1) AR069965A1 (es)
AU (1) AU2008342913A1 (es)
BR (1) BRPI0821432A2 (es)
CA (1) CA2708394C (es)
CL (1) CL2008003920A1 (es)
CO (1) CO6300840A2 (es)
DE (1) DE102007063501A1 (es)
DO (1) DOP2010000200A (es)
EA (1) EA201001006A1 (es)
EC (1) ECSP10010319A (es)
ES (1) ES2397972T3 (es)
HK (1) HK1151801A1 (es)
IL (1) IL205981A0 (es)
NZ (1) NZ586452A (es)
PA (1) PA8809901A1 (es)
PE (1) PE20091186A1 (es)
TW (1) TW200938206A (es)
UY (1) UY31583A1 (es)
WO (1) WO2009083269A1 (es)
ZA (1) ZA201005394B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
KR200497382Y1 (ko) 2023-05-22 2023-10-25 주식회사밀알 마감판 체결이 용이한 침대 프레임 구조

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2918463A (en) 1958-06-12 1959-12-22 Searle & Co 17-carboxyalkylated 17-hydroxy-19-norandrosten-3-ones
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE3410880A1 (de) * 1984-03-21 1985-10-03 Schering AG, Berlin und Bergkamen, 1000 Berlin 17-substituierte estradiene und estratriene
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DE102004063864A1 (de) 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
CA2708394A1 (en) 2009-07-09
AU2008342913A1 (en) 2009-07-09
JP5643107B2 (ja) 2014-12-17
HK1151801A1 (en) 2012-02-10
EP2238150A1 (de) 2010-10-13
TW200938206A (en) 2009-09-16
WO2009083269A1 (de) 2009-07-09
KR20100094999A (ko) 2010-08-27
ECSP10010319A (es) 2010-08-31
DE102007063501A1 (de) 2009-07-02
DOP2010000200A (es) 2010-07-31
CN101910191A (zh) 2010-12-08
US20110015162A1 (en) 2011-01-20
IL205981A0 (en) 2010-11-30
CN101910191B (zh) 2013-07-31
CL2008003920A1 (es) 2010-01-22
EA201001006A1 (ru) 2011-02-28
PA8809901A1 (es) 2009-12-16
JP2011507926A (ja) 2011-03-10
CA2708394C (en) 2015-06-16
AR069965A1 (es) 2010-03-03
EP2238150B1 (de) 2012-10-24
ZA201005394B (en) 2014-01-29
BRPI0821432A2 (pt) 2015-06-16
NZ586452A (en) 2012-04-27
CO6300840A2 (es) 2011-07-21
UY31583A1 (es) 2009-08-03
ES2397972T3 (es) 2013-03-12

Similar Documents

Publication Publication Date Title
ATE485269T1 (de) C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
NO20090835L (no) Nye HIV-reverstranskriptaseinhibitorer
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
ATE541567T1 (de) Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten
ECSP21052586A (es) Glutarato de 3-(1,2,3,6-tetrahidropiridin-2-il)piridina o un solvato farmacéuticamente aceptable del mismo
MD3347349T2 (ro) Derivați de fluoroindol ca modulatori alosterici pozitivi ai receptorilor muscarinici M1
PE20091186A1 (es) DERIVADO DE y-LACTONA DE ESTEROIDE DE ACIDO 15,16-METILEN-17-HIDROXI-19-NOR-21-CARBOXILICO, SU USO Y MEDICAMENTO QUE LO CONTIENE
PE20090822A1 (es) DERIVADO DE 17ß-CIANO-19-NOR-ANDROST-4-ENO, SU USO Y MEDICAMENTO QUE LO CONTIENE
NO20072720L (no) Farmasoytiske sammensetninger basert pa NK2-antagonister for pediatrisk bruk
PE20091185A1 (es) Derivado de 17-(1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen
PE20091181A1 (es) Derivado 15,16-metilen-17-(1'-propenil)-17-3' -oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene
PE20091336A1 (es) Derivados de 19-nor-esteroide que tiene un grupo 15alfa,16alfa-metileno y un anillo de 17,17-espirolactona saturado y composiciones que los comprenden
ATE477820T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung bei der behandlung von adipositas- patienten
PE20091362A1 (es) Derivados de gamma-lactona del esteroide del acido 17-hidroxi-19-nor-21-carboxilico y composiciones que los contienen
CL2020000124A1 (es) Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil.
CU20100138A7 (es) Derivados de 17-(1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen
CU20100140A7 (es) Derivados de 15,16-metilen-17-(1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene
CU20100139A7 (es) Derivados de y-lactona de esteroide de ácido 15,16-metilen-17-hidroxi-19-nor-21-carboxílico, su uso y medicamentos que contienen tal derivado
TH163150B (th) รูปแบบยาของโพรเจสเทอโรนรีเซปเตอร์แอนตะกอนิสต์

Legal Events

Date Code Title Description
FC Refusal